<DOC>
	<DOCNO>NCT00071799</DOCNO>
	<brief_summary>The purpose study determine whether patient high-risk myelodysplastic syndrome ( MDS ) treat azacitidine improve survival compare conventional care treatment . The study also assess effect treatment response , duration response , transformation acute myeloid leukemia ( AML ) . The study continue 12 month follow last patient enrol . See study AZA PH GL 2003 CL 001 E information extension study .</brief_summary>
	<brief_title>A Survival Study Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care</brief_title>
	<detailed_description>Comparison/Control Interventions offer physician three option : - Best supportive care ( BSC ) alone , - Low-dose cytarabine subcutaneously 14 day every 28 42 day , - Standard chemotherapy administer induction continuous intravenous infusion cytarabine 7 day plus anthracycline ( daunorubicin , idarubicin , mitoxantrone ) Days 1 , 2 , 3 ; , eligible , 1 2 consolidation cycle administer continuous intravenous infusion cytarabine 3 7 day anthracycline use induction Days 1 2 ( cycle 28 70 day start previous cycle ) . All three option include best supportive care . Neither experimental group ( azacitidine ) comparison/control option allow use erythropoietin . Duration Intervention : Patients treat death , withdrawal , unacceptable toxicity conclusion study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Have diagnosis refractory anemia excess blast refractory anemia excess blast transformation accord FrenchAmericanBritish classification system myelodysplastic syndrome ( MDS ) relatively high risk acute myeloid leukemia ( AML ) transformation , International Prognostic Scoring System score INT2 High . Be 18 year age old Have life expectancy least 3 month Be unlikely proceed bone marrow stem cell transplantation therapy follow remission Have serum bilirubin level less equal 1.5 time upper limit normal range laboratory Have serum glutamicoxaloacetic transaminase ( aspartate aminotransferase ) serum glutamicpyruvic transaminase ( alanine aminotransferase ) level less equal 2 time upper limit normal ( unless consider related transfusioninduced secondary hemosiderosis ) Have serum creatinine level less equal 1.5 time upper limit normal Secondary myelodysplastic syndrome ( MDS ) Prior treatment azacitidine ; Prior history acute myeloid leukemia ( AML ) ; Malignant disease diagnose within prior 12 month ; Metastatic disease ; Hepatic tumor ; Radiation , chemotherapy , cytotoxic therapy nonMDS condition within prior 12 month ; Prior transplantation cytotoxic therapy treat MDS ; Serious medical illness likely limit survival 12 month less ; Treatment erythropoietin myeloid growth factor prior 21 day androgenic hormone prior 13 day ; Active HIV , viral hepatitis type B C ; Treatment investigational drug prior 30 day ; Within 28day screen period , document red cell folate deficiency , evidence red blood cell folate ( serum folate ) vitamin B12 deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>